HAMBURG, Germany, Aug. 1, 2008 (PRIME NEWSWIRE) -- Evotec AG (Nasdaq:EVTC) (Frankfurt:EVT) announced today that dose escalation studies for a Phase I clinical trial of a small molecule VR1 (vanilloid receptor 1) antagonist is being progressed by Pfizer Inc. under the collaboration with Evotec. The Phase I study is a randomized, double-blind and placebo-controlled single ascending dose study in healthy volunteers to evaluate the compound's safety, tolerability and pharmacokinetic profile after oral administration.
